{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107275","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.507290+00:00","generated_at":"2026-05-17T14:35:13.580861+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Stoke Q2 net loss $23.5M; Phase 3 EMPEROR dosed, 3-year OLE data show durability","bullets":["Net loss $23.5M ($0.40/sh) for Q2 2025 vs $25.7M loss in Q2 2024; H1 net income $89.4M from Biogen collaboration.","First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome; sites active in US, UK, Japan.","New 3-year OLE data show durable seizure reductions and continued improvements in cognition/behavior.","Phase 1 OSPREY study of STK-002 initiated for Autosomal Dominant Optic Atrophy (ADOA).","Cash $355M as of June 30, 2025, expected to fund operations to mid-2028 and into launch readiness."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107275","json":"https://secwatch.observer/filing/0000950170-25-107275.json","markdown":"https://secwatch.observer/filing/0000950170-25-107275.md","text":"https://secwatch.observer/filing/0000950170-25-107275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000095017025107275/0000950170-25-107275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000095017025107275/stok-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:35:13.580861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}